Sepiapterin, sold under the brand name Sephience, is a medication used for the treatment of hyperphenylalaninemia. Sepiapterin is a phenylalanine hydroxylase activator. It is also metabolite that is naturally synthesized in the human body. Chemically it is a pterin derivative that enters the BH4 salvage pathway and is enzymatically reduced to dihydrobiopterin and tetrahydrobiopterin, thereby supporting phenylalanine hydroxylase cofactor availability. As an active pharmaceutical ingredient it is characterized by high polarity, stability in dry form, and predictable conversion to downstream pterins in vivo. Analytical control typically uses reversed phase HPLC with UV detection and orthogonal confirmation by LC-MS and NMR; formulation development has focused on oral dosage forms with attention to hygroscopicity and light sensitivity.
Typical quality specifications for sepiapterin API include assay by HPLC on dried basis 98.0 to 102.0 percent, water content by Karl Fischer not greater than 0.5 percent, and heavy metals not greater than 10 parts per million. Residual solvents are controlled to meet ICH Q3C limits for Class 2 and Class 3 solvents, for example methanol limited to 3000 ppm when applicable. Related substances are monitored by validated HPLC and LC-MS methods; a common specification framework limits any individual unidentified impurity to not more than 0.10 to 0.20 percent and total impurities to not exceed 0.5 to 1.0 percent. Known related compounds and endogenous metabolites to monitor include tetrahydrobiopterin (BH4), dihydrobiopterin (BH2), and other pterin derivatives, which as manufacturing- or degradation-related species are typically controlled to low single-digit tenths of a percent each and identified by reference standards.
Sepiapterin is a pterin derivative and endogenous metabolite that serves as a precursor in the BH4 salvage pathway and acts pharmacologically as a phenylalanine hydroxylase activator to support reduction of phenylalanine levels.
Sepiapterin is not currently an FDA-approved therapeutic product; its clinical and regulatory status depends on sponsor submissions and local regulatory reviews, so check authoritative regulatory sources or the product manufacturer for the latest status.
Commercial availability depends on completed clinical development and regulatory approval; until such approvals are granted it may be accessible only through clinical trials, named-patient programs, or direct contact with the manufacturer for program-specific timelines.
